Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats

European Journal of Pharmacology

Volumn 416, Issue 1-2, 2001, Pages 133-139

  Naderali, Ebrahim K ^a   Pickavance, Lucy C ^a   Wilding, John P H ^a   Doyle, Patrick J ^b   Williams, Gareth ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Endothelium; Obesity; Troglitazone; Vascular dysfunction

Indexed keywords

ACETYLCHOLINE; FAT; FATTY ACID; INSULIN; LEPTIN; NITROPRUSSIDE SODIUM; NORADRENALIN; POTASSIUM CHLORIDE; TRIACYLGLYCEROL; TROGLITAZONE;

ARTICLE; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FATTY ACID BLOOD LEVEL; FEMALE; MESENTERIC ARTERY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; VASODILATATION;

ACETYLCHOLINE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHROMANS; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN; LEPTIN; MESENTERIC ARTERIES; NITROPRUSSIDE; NOREPINEPHRINE; OBESITY; POTASSIUM CHLORIDE; RATS; RATS, WISTAR; THIAZOLES; THIAZOLIDINEDIONES; TRIGLYCERIDES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 0035937521     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00866-4     Document Type: Article

References (49)

1. Role of endothelial dysfunction in coronary artery disease
2. Marked hyperinulinaemia produces both sympathic nueral activation and vasodilataion in normal humans
3. Secondary endothelial dysfunction: Hypertension and heart failure
4. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect
5. Growth-promoting effects of diabetes and insulin on arteries. An in vivo study of the rat aorta
6. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The nurses' health study
7. Mesenteric arcade arteries contribute substantially to vascular resistance in conscious rats
8. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients
9. Impaired vasodilatation of forearm resistance vessels in hypercholesterolemic humans
10. Insulin-mediated vasodilation: Impairment with increased blood pressure and body mass
11. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats
12. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The troglitazone study group
13. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function
14. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs
15. Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery
16. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
17. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance
18. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM
19. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates
20. Expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in rat aortic smooth muscle cells
21. Prevalence of insulin resistance in essential hypertension
22. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
23. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus
24. Endothelial dysfunction: From physiology to therapy
25. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
26. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats
27. Evidence of impaired endothelial function in dietary-induced obese rats
28. Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs
29. Inhibitory action of insulin-sensitising agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig
30. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
31. Vascular wall reactivity in conductance and resistance arteries: Differential effects of insulin resistance
32. Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb
33. Therapeutic index for rosiglitazone in dietary obese rats: Separation of efficacy and haemodilution
34. Endothelial dysfunction: Cause of the insulin resistance syndrome
35. Role of insulin resistance in human disease
36. Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine
37. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats
38. Primary endothelial dysfunction: Atherosclerosis
39. Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production
40. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release
41. Obesity/insulin resistance is associated with endothelial dysfunction: Implications for the syndrome of insulin resistance
42. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
43. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone
44. Impaired insulin-induced attenuation of noradrenaline-mediated vasoconstriction in insulin-resistant obese Zucker rats
45. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro
46. Impaired endothelium-dependent and independent dilatation of forearm arteries in men with diet-treated non-insulin-dependent diabetes: Role of dyslipidaemia
47. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
48. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats
49. Antihypertensive effects of CS-045 treatment in obese Zucker rats